Segmentation by type classifies the market into CRISPR/Cas9, TALEN, zinc‑finger nucleases (ZFNs), transgenic, knockout, and knock‑in approaches, each influencing market dynamics through distinct technical capabilities and cost structures. CRISPR/Cas9, with its high editing efficiency and scalability, now commands the largest share, driving growth through widespread adoption across academic and commercial labs. TALEN and ZFN, though older, retain niche relevance for applications requiring reduced off‑target activity, contributing modest but stable revenue streams. Transgenic models, created via pronuclear injection or viral vectors, remain essential for over‑expression studies, sustaining a significant portion of the market despite emerging gene‑editing alternatives. Knockout technologies, historically the backbone of functional genomics, continue to generate demand for loss‑of‑function models, while knock‑in strategies, enabling precise allele replacement, are expanding rapidly as precision‑medicine initiatives intensify. The interplay of these types determines overall market valuation by reflecting R&D preferences, regulatory acceptance, and the evolving complexity of genetic‑engineering projects.